Research Reports

Summary

PMV Pharmaceuticals reported Q1 2026 net loss of $18.0 million, with R&D expenses down 12% year-over-year, and disclosed $93.5 million in cash as of March 31, 2026, supporting a cash runway to end-Q2 2027, alongside key clinical progress for rezatapopt including 44% ORR in TP53 Y220C ovarian cancer and planned NDA submission in Q1 2027.

Key takeaways

Rezatapopt achieved 44% ORR (32/72) in platinum-resistant/refractory ovarian cancer patients with TP53 Y220C mutation per investigator assessment under RECIST 1.1 — signals potential registrational efficacy.

FDA granted Orphan Drug Designation for rezatapopt in TP53 Y220C-positive ovarian, fallopian tube, and primary peritoneal cancers — enables fee exemptions, development incentives, and 7-year U.S. market exclusivity upon approval.

NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer is planned for Q1 2027 — establishes near-term regulatory catalyst and validates clinical development timeline.

Cash, cash equivalents, and marketable securities totaled $93.5 million as of March 31, 2026, providing expected cash runway through end of Q2 2027 — supports ongoing PYNNACLE Phase 2 enrollment and NDA preparation without near-term dilution.

Q1 2026 net loss was $18.0 million vs $17.4 million in Q1 2025; R&D expenses decreased to $15.3 million from $17.4 million — driven by lower CRO costs for rezatapopt advancement.

Full analysis

PMV Pharmaceuticals’ Q1 2026 results reflect disciplined expense management amid advancing clinical execution: R&D spend declined 12% year-over-year to $15.3 million, primarily due to reduced CRO costs for the rezatapopt program, while G&A fell 10% to $3.7 million on lower personnel and professional fees. Net loss increased modestly to $18.0 million from $17.4 million, largely attributable to the absence of a $2.2 million NOL carryforward sale benefit recognized in Q1 2025 — a non-recurring item that distorts YoY comparison. Critically, the company ended the quarter with $93.5 million in total liquid assets, down from $112.9 million at year-end, implying ~$19.7 million in net cash used in operations — consistent with its stated burn rate and supporting the disclosed cash runway through end-Q2 2027. This liquidity position enables continued enrollment in the registrational Phase 2 PYNNACLE trial, where updated data showed a 44% ORR (32/72) in TP53 Y220C platinum-resistant/refractory ovarian cancer — a clinically meaningful signal reinforced by publication of first-in-human data in the New England Journal of Medicine and FDA Orphan Drug Designation across three gynecologic cancers. Management reaffirmed its Q1 2027 NDA submission target, anchoring near-term value inflection to regulatory filing rather than further clinical data reads. With no revenue, the financials serve purely as a runway and operational efficiency indicator — and the company remains on track to reach its next major milestone without equity financing.